One of the industries, in the grip of immense innovation, is the pharmaceutical one. The industry is also seeing tremendous diversification. Some of the most successful movers during this stage will be characterized by their move towards strategic differentiation, rather than by in- house discoveries. Their business research and development models will need to be increasingly virtualized. The decision making needs to be rapid, incorporating a reallocation of the resources. Pharma companies are also able to track greater quantities of business intelligence thanks to the enormous data profusion from patient use. This is helping is better therapy design. The studies are now being run in a more agile manner. Even the industry regulators are taking a break, allowing quicker connect between the patients and medicines. Value and evidence are increasingly getting aligned.

Source:https://www.mckinsey.com/industries/pharmaceuticals-and-medical-products/our-insights/r-and-d-in-the-age-of-agile

Uploaded Date:02 February 2019